India Pharma Conference 2026 to spotlight innovation, global partnerships in New Delhi

Discussions are likely to centre on how the country can move up the pharmaceutical value chain

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

RoosterBio taps MineBio to supercharge hMSC & exosome solutions in China

Merck expands Bengaluru plant to strengthen global filtration supply chain

New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

HRV Pharma, Shodhana join hands to build next-gen API pipeline for global markets

Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets

Dr Jitendra Singh calls for India-led biosimilar insulin scale-up amid global supply concerns

Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation

Senores makes bold US push with new federal-focused JV

Company leadership is framing the move as transformational.

India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push

DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports

Nearly 40 industry groups unite to push for EU Biotech Act II

A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative